Literature DB >> 25652036

Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).

R Martino1, G Bautista, R Parody, I García, A Esquirol, M Rovira, J R Cabrera, C Regidor, R Fores, J A García-Marco, D Serrano, P Barba, I Heras, F J Marquez-Malaver, I Sánchez-Ortega, R Duarte, S Saavedra, J Sierra, L Vazquez.   

Abstract

BACKGROUND: Umbilical cord blood transplantation (CBT) is an established alternative source of stem cells in the setting of unrelated transplantation. When compared with other sources, single-unit CBT (sCBT) is associated with a delayed hematologic recovery, which may lead to a higher infection-related mortality (IRM). Co-infusion with the sCBT of CD34+ peripheral blood stem cells from a third-party donor (TPD) (sCBT + TPDCD34+) has been shown to markedly accelerate leukocyte recovery, potentially reducing the IRM. However, to our knowledge, no comparative studies have focused on severe infections and IRM with these 2 sCBT strategies.
METHODS: A total of 148 consecutive sCBT (2000-2010, median follow-up 4.5 years) were included in a multicenter retrospective study to analyze the incidence and risk factors of IRM and severe viral and invasive fungal infections (IFIs). Neutrophil engraftment occurred in 90% of sCBT (n = 77) and 94% sCBT + TPDCD34+ (n = 71) recipients at a median of 23 and 12 days post transplantation, respectively (P < 0.01).
RESULTS: The 4-year IRM was 24% and 20%, respectively (P = 0.7), with no differences at day +30 (5% and 4%, respectively) and day +100 (10% and 8%, respectively). In multivariate analysis early status of the underlying malignancy, cytomegalovirus (CMV)-seronegative recipient and high CD34+ cell content in the cord blood unit before cryostorage (≥1.4 × 10(5) /kg) were protective of IRM. Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs. 4%), while CMV disease and parasitic infections were more common in the sCBT + TPDCD34+ cohort (5% vs. 16%).
CONCLUSION: These data show that sCBT supported with TPDCD34(+) cells results in much shorter periods of post-transplant leukopenia, but the short- and long-term rates of IRM were comparable to those of sCBT, presumably because immune recovery is equally delayed in both graft types.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic; cord blood transplantation; severe infections

Mesh:

Substances:

Year:  2015        PMID: 25652036     DOI: 10.1111/tid.12361

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  4 in total

1.  Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Marisa H Miceli; Tracey Churay; Thomas Braun; Carol A Kauffman; Daniel R Couriel
Journal:  Mycopathologia       Date:  2017-01-25       Impact factor: 2.574

Review 2.  Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Authors:  Juan Montoro; José Luis Piñana; Federico Moscardó; Jaime Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-18       Impact factor: 2.576

3.  Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy.

Authors:  Kathleen A Linder; Philip J McDonald; Carol A Kauffman; Sanjay G Revankar; Pranatharthi H Chandrasekar; Marisa H Miceli
Journal:  Open Forum Infect Dis       Date:  2019-02-22       Impact factor: 3.835

4.  Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching.

Authors:  Sierra Jorge; Martino Rodrigo; García-Cadenas Irene; Esquirol Albert; Bosch-Vilaseca Anna; Awol Rahinatu; Novelli Silvana; Saavedra Silvana; Garrido Ana; López Jordi; Caballero Ana Carolina; Granell Miquel; Moreno Carolina; Briones Javier
Journal:  Bone Marrow Transplant       Date:  2020-10-26       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.